AllDocs -> cancers

Pacific Ovarian Cancer Research Consortium Advocacy Group Meeting Minutes 02/22/02 Welcome and Updates: The meeting began with the reading of the mission statement. We then went around the room telling how, as advocates, we planned to meet the needs of the patient. New Member Mentoring : Sheryl would like to start a new mentoring program where new advocates will be paired up with seasoned advocates. This will hopefully enhance the new member experience. Lab Tour : We have been asked to tour Seattle Genetics lab. They do not currently research ovarian cancer , but would like to add it to the list of cancers they do study and feel that advocates can help. Advocates in Action: CRP update: Sheryl reported on her experiences on the California Review Program. 5 committees attended and she was part of the clinical committee. There were 17 researchers, physicians and surgeons as well ...

Minutes Pacific Ovarian Cancer Research Consortium (POCRC) Advocate Meeting January 31, 2003 Sze Conf. Room, Fred Hutchinson Day Campus Kathy C. O’Briant, M.S: Biology of Ovarian Cancer . Kathy did an outstanding job of explaining and simplifying the biology of ovarian cancer through her presentation and handouts. A lively question and answer period followed. Call the advocacy office (206-667-5717) if you would like to receive a copy of Kathy’s handouts. Note from Advocacy Program Coordinator, Sheryl Eisenbarth: Sheryl was unable to attend the meeting due to a recent chemotherapy treatment. The good news is that this is her last BIG chemotherapy treatment! The advocates wish her the best and look forward to seeing her at the next meeting on February 28. Program for the Advocates’ Spring Welcome on March 1, 2003: The advocates reviewed the draft program for the Spring Welcome ...

Pacific Ovarian Cancer Research Consortium (POCRC) Advocate Quarterly Meeting Saturday, September 29, 2001 9:00 AM - 1:00 PM Minutes Introductions: Sheryl Eisenbarth, POCRC Patient Advocacy Coordinator, started the meeting by inviting each advocate to introduce herself and share why they were part of the POCRC advocate group. It was decided that each meeting will begin with an “Advocate in Action” story. Ovarian Cancer National Alliance (OCNA) Advocacy Conference: Shirley Inveen shared her experience at the OCNA Conference “ Ovarian Cancer : Silent No More” held 9/19-22, 2001 in Indianapolis, IN. Shirley had to leave her Gig Harbor home at 3:00 AM in the morning to catch her flight and represent us at the conference! Free webcasts of the conference can be viewed at www.cancereducation.com . Sessions included cancer genetics, new and promising treatment therapies, prolonging ...

The American Cancer Society esti- mates that 25,580 new cases of ovarian cancer will be diagnosed and 16,090 women will die of the disease during 2004. Among U.S. women, ovarian cancer is the se- venth most common cancer and the fifth leading cause of cancer death after lung and bronchus, breast, colorectal, and pancreatic cancers. Ovarian cancer causes more deaths than any other cancer of the female reproductive system. Although the U.S. ovarian cancer incidence rate has changed little since 1975,the mortality rate has decreased by about 9%. According to the National Cancer Institute,from 1996–2000,the age-adjusted ovarian cancer incidence rate for white women (17.9 cancers per 100,000 women) was higher than the corre- sponding rates for Hispanics (14.0), Asians/Pacific Islanders (12.2),blacks (11.9) and American Indians/Alaska ...

The American Cancer Society pre- dicts that in 2003, about 25,400 new cases of ovarian cancer will be diagnosed and 14,300 women will die of the disease. Among U.S. women, ovarian cancer is the sev- enth most common cancer and the fifth leading cause of cancer death after lung and bronchus, breast, col- orectal, and pancreatic cancers. Ovarian cancer causes more deaths than any other type of gynecologic cancer and accounts for 5% of all cancer deaths among women. Although the U.S. incidence rate has changed little since 1973, the mor- tality rate has decreased by about 12%. In 1999, the age-adjusted inci- dence rate for white women—17.6 cancers per 100,000 women—was higher than the corresponding rates for Asians/Pacific Islanders (13.1), Hispanics (12.0), and blacks (11.8). The Burden of Ovarian Cancer Who Is at Risk? ...

The Use of Ultrasound in Diagnosing Ovarian Cancer : Can We Improve on Current Practice? May 14, 2002 Final Workshop Summary Division of Cancer Prevention and Control National Center for Chronic Disease Prevention and Control Centers for Disease Control and Prevention Atlanta, Georgia Prepared by: Christie Eheman, PhD 1 ; Jennifer Brustrom, PhD 2 ; and Herschel Lawson, MD 1 1 Division of Cancer Prevention and Control 2 Battelle Centers for Public Health Research and Evaluation Page 2 2 Table of Contents Page Workshop Agenda 3 Introduction/Purpose 4 Summary of Roundtable Discussions Factors Affecting the Quality of Ultrasound Examinations 5 Activities Proposed for Improving the Diagnostic Use of Ultrasound ...

SCIENCE IN BRIEF : Ovarian Cancer For more information, please contact: The Centers for Disease Control and Prevention • National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control • Mail Stop K-64, 4770 Buford Highway, NE • Atlanta, GA 30341-3717 • Phone (770) 488-4751 Fax (770) 488-4760 • Voice Information System 1 (888) 842-6355 • E-mail cancerinfo@cdc.gov • Web site http://www.cdc.gov/canceryyy Department of Health and Human Services Centers for Disease Control and Prevention 2004/2005 FROM THE DIVISION OF CANCER PREVENTION AND CONTROL Health Care-Seeking Behaviors Among Women Experiencing Symptoms Suggestive of Ovarian Cancer A research project with the University of Texas Health Science Center at Houston is assessing health care-seeking behaviors among women ...

Thursday, July 27th OTZ Fundraiser for Ovarian Cancer ! 20% of your lunch, dinner & carryout sales will benefit Petal by Petal Trust Fund Flyer distribution on Max & Erma's property is prohibited and will result in the forfeiture of your organization's entire donation. Proceed donation does not include gift certificate sales. Present this ticket to your Max & Ermas server and 20% of your lunch, dinner & carryout sales will benefit Petal by Petal Trust Fund OTZ Fundraiser for Ovarian Cancer ! Polaris 1515 Polaris Pkwy., 614-840-9466 Thursday, July 27th OTZ Fundraiser for Ovarian Cancer ! 20% of your lunch, dinner & carryout sales will benefit Petal by Petal Trust Fund Flyer distribution on Max & Erma's property is prohibited and will result in the forfeiture of your organization's entire ...

What are the facts on Ovarian Cancer ? Garvan Institute of Medical Research What is ovarian cancer ? The ovaries are small almond-shaped organs located at both sides of the uterus. They are responsible for producing ova- the female reproductive cells, and the hormones oestrogen and progesterone. Ovarian cancer occurs when the normal division and growth of ovarian cells is disrupted, leading to an uncontrollable build up of cells. These abnormal build- ups are typically in the epithelial cells covering the ovary, but can also happen in the hormone producing tissues or in the ovum itself. Without appropriate treatment, the abnormal cancer cells may spread to nearby tissues or organs. How common is it? Ovarian cancer is the fourth leading cause of female cancers with 1 in 90 women estimated to develop the disease at some point in their ...

A SYSTEMS BIOLOGY CASE STUDY OF OVARIAN CANCER DRUG RESISTANCE Jake Y. Chen 1,2 , Changyu Shen 3 , Zhong Yan 1 , Dawn P. G. Brown 4 , Mu Wang 4 1 Indiana University School of Informatics, IUPUI, Indianapolis, IN 46202; 2 Department of Computer and Information Science, Purdue University School of Science, IUPUI, Indianapolis, IN 46202; 3 Division of Biostatistics, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202; 3 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202 In ovarian cancer treatment, the chemotherapy drug cisplatin often induce drug resistance after prolonged use, causing cancer relapse and the eventual deaths of patients. Cisplatin-induced drug resistance is known to involve ...

Page 2 Mortality trends in England; ICD9 (183), ICD10 (C56); File: Sepho 96-04 V2 Ovarian cancer in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for ovarian cancer in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

Walking in memory of those who have courageously gone before us, for those currently fighting every day and for those who have not yet started their fight. For registration, fundraising tips and the latest walk information visit our web-site at: teamspiritonline.org or call 562/896-4037 5520 E. Second St., #E-217 L ong Beac h, C A 9 0 8 03 www .teamspiritonline.org SATURDAY OCTOBER 7, 2006 TEAM SPIRIT BREAST & OVARIAN CANCER 10K WALK Page 2 M ake a commitment and join the fight against breast and ovarian cancers. Join us on Saturday, October 7, 2006 to celebrate life and remember those who have lost their fight. Please note 100% of the monies raised (non-registration fees) ...

Genetic testing for susceptibility to breast and ovarian cancer : Evaluating the impact of a direct-to-consumer marketing campaign on physicians’ knowledge and practices Melanie F. Myers, PhD, MS 1 , Man-Huei Chang, MPH 1 , Cynthia Jorgensen, PhD 2 , William Whitworth, MPH 1 , Sidibe Kassim, MD 3 , James A. Litch, MD, DTMH 3 , Lori Armstrong, PhD 4 , Barbara Bernhardt, MS 5 , W. Andrew Faucett, MS 6 , Debra Irwin, PhD, MSPH 7 , Judy Mouchawar, MD, MSPH 8 , and Linda A. Bradley, PhD 1 Purpose: To assess the impact of direct-to-consumer marketing of genetic testing for risk of breast and ovarian cancer by a biotechnology company on: 1) physicians’ knowledge; 2) reasons ...

OVARIAN CANCER RESEARCH FUND, INC. OVARIAN CANCER RESEARCH TRAINING PROGRAMS OF EXCELLENCE __ 2006 The OVARIAN CANCER RESEARCH TRAINING PROGRAMS OF EXCELLENCE award provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Trainees may be involved in either laboratory, clinical or epidemiology research. Those eligible to apply include: 1) Clinical fellows (Gynecologic Oncology, Medical Oncology, etc.) 2) Post-doctoral fellows Awards will be made to approximately six individuals working in institutions with well-developed ovarian cancer research programs. In addition to the strength of the research environment and project proposal, selection criteria include the trainee’s prior academic track record and the likelihood of them pursuing a research career. The research plan ...

Ovarian Cancer Research Fund, Inc. (OCRF) Program Project Development Grant 2006 Purpose The purpose of this program is to provide funds that can be used by groups of investigators seeking to develop program project grant applications for submission to peer-review funding agencies (eg. NCI PO1, SPORE, DOD). This may involve several investigators within one institution or collaborations between groups in multiple institutions. Areas of emphasis include screening and early detection, etiology and prevention, molecular therapeutics, cancer biology and genetics. Eligibility The Principal Investigator and other investigators must have full-time faculty appointments in a school of medicine or public health or recognized scientific research facility. They should not currently be in a training program. Timeline Grant applications are due August 20, 2006 and ...

348 COMMUNITY ONCOLOGY ¦ June 2006 www.CommunityOncology.net Community Translations © 2006 Elsevier Inc. All rights reserved. Steven J. Tucker, MD, Section Editor The Angeles Clinic & Research Institute, Los Angeles, CA Commun Oncol 2006;3:348–353 A recently reported Gy- necologic Oncology Group (GOG) trial 1,2 showed a remarkable 15.9-monthincreasein median overall survival for intraperito- neal (IP) versus intravenous (IV) che- motherapy among patients with newly diagnosed stage III ovarian carcinoma or primary peritoneal carcinoma. Intraperitoneal therapy for stage III optimally debulked ovarian cancer Should women with optimally resected stage III ovarian cancer be treated with intraperitoneal (IP) cisplatin and a taxane rather than the universally accepted standard of care—a combination ...

*ffiwsmW An ovarian cancer redesign NOCA adopts QB woman's idea for redesigning space for women By ALLI VAIL Nrws Rnponrnn Sharon Wood has gone out of her way to learn everything she can about one of the last things anyone wants to talk about - ovar- ian cancer . Wood's mother died of the disease when she was 65 years old. "I remember thinking she had a good life, she was old," says Wood. Now, at 62 years of age herself, the Qualicum Beach resident knows bet- ter. Ovarian cancer can go undetected for a long time because there are no specific symptoms. According to the National Ovarian Cancer Association (NOCA) the symptoms are vague swelling abdomens, pelvic discomfort, back or abdom- inal pain, fatigue, nausea, indigestion, weight loss or weight gain, ...

www.canadianredesigners.org 2716 Dufferin Ave.Victoria, BC V8R 3L4 tel: 250-598-5848 fax: 250-598-0501 email: info@canadianredesigners.org 1 MEDIA RELEASE FOR IMMEDIATE RELEASE Canadian Redesigners to Create Havens for National Ovarian Cancer Association VICTORIA, September 23, 2005 . At their annual conference this past weekend in Victoria, Canadian Redesigners kicked off their support of the National Ovarian Cancer Association (NOCA) as their charity of choice. Members of the association across Canada will be offering their services to create a comfortable haven in the family home for women in treatment for this disease. “Redesign is about creating homes that people love using what they already have,” says Val Sharp, President of the Canadian Redesigners Association (CRDA). “Supporting NOCA in this manner is just an extension of what we already ...

MB1013 OriGene TissueScan Ovarian Cancer Matched TMA 1 2 3 4 5 6 7 8 9 10 11 12 Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Normal Normal Normal Normal Normal Normal Normal Tumor Tumor Tumor Tumor Tumor A CU0000005619 CI0000008705 CI0000000027 CI0000008510 CI0000010025 CI0000010025 CU0000006486 CI0000008190 CI0000000453 CI0000008501 CI0000009464 CI0000009760 HE HE HE HE HE HE HE HE HE HE HE HE Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Ovary Tumor Tumor Tumor Tumor Tumor Tumor ...

MB59 Ovarian Cancer Array 1 2 3 4 5 Ovary Ovary Ovary Ovary Ovary Tumor Tumor Tumor Tumor Tumor A CI0000000069 CI0000000097 CI0000000085 CI0000000125 CI0000000208 HE HE HE HE HE Ovary Ovary Ovary Ovary Ovary Tumor Tumor Tumor Tumor Tumor B CI0000000210 CI0000000417 CI0000000453 CI0000000476 CI0000000485 HE HE HE HE HE Ovary Ovary Ovary Ovary Ovary Tumor Tumor Tumor Tumor Tumor C CI0000005047 CI0000005554 CI0000005666 CI0000005761 CI0000005939 HE HE HE HE HE Ovary Ovary Ovary Ovary Ovary Tumor Tumor Tumor Tumor Tumor ...

Page 1 of 2 For Immediate Release: Ciphergen Biosystems, Inc. Sue Carruthers Investor Relations (510) 505 2297 Ciphergen reports positive results from multi-center validation ovarian cancer biomarker study Results presented at the annual meeting of the American Society of Clinical Oncology Fremont, CA, June 5, 2006 - Ciphergen Biosystems, Inc. (Nasdaq:CIPH) announced today results of a multi-center study evaluating the performance of a set of seven biomarkers for the detection of ovarian cancer . 607 patient samples taken from five international medical centers were evaluated for each of the seven markers. 234 women had benign gynecologic disease and 373 patients had invasive epithelial ovarian cancer , including 101 with early stage cancer . All seven biomarkers individually demonstrated statistically significant power to differentiate ovarian cancer patients ...

1 APPLICATION OF A POLYGENIC MODEL OF BREAST AND OVARIAN CANCER TO CRITICAL ILLNESS INSURANCE By Angus Macdonald and Kenneth McIvor abstract Mutations in the BRCA1 and BRCA2 genes confer very high risk of breast cancer (BC) but only account for about 25% of the observed familial clustering of BC. Antoniou et al. (2002) proposed a model that included the BRCA1 and BRCA2 genes, and a polygenic component that acted multiplicatively on the rate of onset of BC. We use this model to find premium rates for critical illness insurance: (a) given knowledge of an applicant’s polygenotype; and (b) given knowledge of a family history of BC or ovarian cancer . We find that the polygenic component causes large variation in premium rates even among non-mutation carriers, therefore affecting the whole population. In some cases the polygenic contribution is protective enough to reduce or remove the additional risk ...

A FREE Course for all ovarian cancer survivors, friends, family members and others who are interested in hearing from the leading experts in ovarian cancer research. These experts will share new information about ovarian cancer , and time for questions and answers will be provided. Saturday, October 14, 2006 8:00 a.m. – 9:00 a.m. Registration 9:00 a.m. – 4:00 p.m. Course Refreshments will be provided during the Break and Roundtable Luncheon Loews Santa Monica Beach Hotel Meeting Room: Palisades 1700 Ocean Avenue • Santa Monica, CA 90401 (310) 458-6700 www.thegcf.org www.wcn.org Funding for this conference was made possible in part by H13/CCH524979-01 from The National Center for Chronic Disease Prevention and Health Promotion. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily ...

A FREE Course for all ovarian cancer survivors, friends, family members and others who are interested in hearing from the leading U.S. experts in ovarian cancer research. These experts will share new information about ovarian cancer ,and time for questions and answers will be provided. Saturday, September 16, 2006 9:00 a.m. – 10:00 a.m. Registration 10:00 a.m. – 4:00 p.m. Course Washington University School of Medicine Eric P. Newman Education Center 320 S. Euclid • St. Louis, MO 63110 www.thegcf.org www.wcn.org GYNECOLOGIC CANCER FOUNDA TION 230 W MONROE ST STE 2528 CHICAGO IL 60606-9416 NO POST AGE NECESSAR Y IF MAILED IN THE UNITED ST A TES BUSINESS REPL Y MAIL FIRST -CLASS MAIL PERMIT NO. 507 CHICAGO IL POST AGE WILL BE ...

A FREE Course for all endometrial cancer survivors, friends, family members and others who are interested in hearing from the leading U.S.experts in endometrial cancer research. These experts will share new information about endometrial cancer , and time for questions and answers will be provided. Saturday, September 30, 2006 8:00 a.m. – 9:00 a.m. Registration 9:00 a.m. – 4:00 p.m. Course Lunch will be provided The University of Texas M. D. Anderson Cancer Center Cancer Prevention Building • 8th Floor • Rooms 5-8 1155 Pressler • Houston, TX 77030 www.thegcf.org www.wcn.org www.mdanderson.org GYNECOLOGIC CANCER FOUNDA TION 230 W MONROE ST STE 2528 CHICAGO IL 60606-9416 NO POST AGE NECESSAR Y IF MAILED IN THE UNITED ST A TES BUSINESS REPL Y MAIL FIRST ...

Raine's legacy: Ovarian cancer awareness by LYN JERDE - SUN NEWSPAPERS (Created: Wednesday, May 17, 2006 9:07 PM CDT) Lorraine "Raine" Snyder had planned to attend last week's annual meeting of the Minnesota Ovarian Cancer Alliance (MOCA), to inaugurate a fund in her name for the education of physicians about ovarian cancer . But the disease claimed her life, at age 56, on May 4. On May 9 - the day after her memorial service at St. Andrew Lutheran Church, Eden Prairie - her husband, Tripp Snyder, attended the MOCA annual meeting in Edina, accompanied by numerous family members and friends. "We just turned the podium over to Tripp," said Kathleen Gavin, executive director of the St. Louis Park-based MOCA. "And he made some moving, and sometimes hard-hitting remarks." Among the audience members were physicians, who heard Tripp Snyder declare that doctors had failed his wife when they misdiagnosed ...

Early Detection of Ovarian Cancer Cells using Silica Nanowires and CA125 Biomarkers Niranjan Ramgir 1 , Praveen Kumar Sekhar 1 , Aleksandra Zajac 2 , Tatyana Zhukov 2* , Shekhar Bhansali 1* 1 BioMEMS and Microsystems Laboratory, Department of Electrical Engineering, University of South Florida, 4202 E. Fowler Ave, ENB118, Tampa, FL-33620 Tel: (813) 974 3593, Fax: (813) 974 5250 Email: bhansali@eng.usf.edu 2 Department of Interdisciplinary Oncology, College of Medicine H. Lee Moffitt Cancer Center and Research Institute The University of South Florida, 12902 Magnolia Dr. Tampa, Fl 33612 Phone: 1-888-MOFFITT (1-888-663-3488). Email: ZhukovTA@moffitt.usf.edu Abstract In this work, an electrochemical bio-sensor using aligned silica nanowires in a micro-fluidic platform is proposed ...

Page 1 of 9 Coverage Position Number: 0321 C IGNA H EALTH C ARE C OVERAGE P OSITION Subject Stem-Cell Transplant for Ovarian Cancer Revised Date ..4/15/2006 Original Effective Date .4/15/2005 Coverage Position Number . 0321 Table of Contents Coverage Position..1 General Background .1 Coding/Billing Information..7 References.8 Hyperlink to Related Coverage Positions INSTRUCTIONS FOR USE Coverage Positions are intended to supplement certain standard CIGNA HealthCare benefit plans. Please note, the terms of a participant’s particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard ...

100 Title 3—The President Proc. 7919 founding of the country and was furthered by the 1848 women’s rights con- vention in Seneca Falls, New York. By celebrating Women’s Equality Day, we commemorate the adoption of this amendment and honor the visionary women who fought tirelessly for women’s suffrage. Led by women such as Elizabeth Cady Stanton, Susan B. Anthony, and Lucretia Mott, the suffragists stood up against injustice and persevered until, as Susan B. Anthony wrote, the handful who first took a stand for suffrage grew into an army. The efforts of these pioneers helped secure for American women the right to vote. Since the adoption of the 19th Amendment, women have continued to make great contributions to our Nation. Women today are leaders in medi- cine, law, journalism, business, government, and other professions. They are doctors and mothers, teachers and lawyers, homemakers ...

CALIFORNIA STATE SCIENCE FAIR 2006 PROJECT SUMMARY Ap2/06 Name(s) Project Number Project Title Abstract Summary Statement Help Received Sarah L. Barr The Effect of Age at First Menstruation on Ovarian Cancer Development S1002 Objectives/Goals The purpose of this experiment was to test whether there is any correlation between the age of first menstruation in a girl who develops ovarian cancer , and the girl's age when the cancer develops. Methods/Materials I gathered data for my project by using the Internet to contact ovarian cancer support groups and message boards. I created a simple questionnaire to gather specific pieces of data which included the age at first menstruation, the age at cancer development, type of cancer , and whether or not the subject had given birth. All responses to the questionnaire were ...